You are here

bimekizumab

UCB Wins FDA Approval for Plaque Psoriasis Therapy After Regulatory Setbacks

BioSpace

Thu, 10/19/23 - 10:15 am

UCB's bimekizumab finally back on the FDA's review list after May rejection

Fierce Pharma

Wed, 12/28/22 - 08:40 pm

UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug

MedCity News

Sun, 05/15/22 - 11:12 pm

From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year

Fierce Pharma

Mon, 09/13/21 - 11:38 pm

Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021

PR Newswire

Tue, 03/9/21 - 10:45 am

UCB touts another psoriasis win, this time over Cosentyx, as they look to break into packed market

Endpoints

Fri, 07/24/20 - 11:17 am

UCB’s growth driver squares up against the competition

EP Vantage

Thu, 06/11/20 - 12:20 pm

clinical trials

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Fri, 12/6/19 - 09:31 pm

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Endpoints

Fri, 11/15/19 - 11:12 am

clinical trials

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

Fierce Biotech

Fri, 10/18/19 - 07:47 pm

bispecific antibodies

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

Endpoints

Thu, 10/17/19 - 10:24 am